Stock Information
symbol line chart

LFCRLifecore Biomedical Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

James G. Hall

Location

Minnesota, USA

Exchange

Nasdaq

Website

https://www.landec.com

Summary

Landec Corporation engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets.

Company Info

CEO

James G. Hall

Location

Minnesota, USA

Exchange

Nasdaq

Website

https://www.landec.com

Summary

Landec Corporation engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets.

AI Insights for LFCR
3 min read

Quick Summary

Lifecore Biomedical Inc. is a Nasdaq-listed contract development and manufacturing organization focused on pharmaceutical and medical-grade biomaterials, with a particular emphasis on sterile injectable products and hyaluronic acid-based materials. The provided company description still references Landec Corporation and its historical food businesses, but the operating identity represented by LFCR is Lifecore Biomedical, which is centered on pharmaceutical products rather than packaged foods. The company designs, develops, manufactures, and supports commercial production for customers that need high-quality injectable fill-finish, formulation, and biomaterial manufacturing capabilities. Its customers are primarily pharmaceutical, biotechnology, medical device, and aesthetics companies that outsource complex sterile manufacturing or need specialized hyaluronic acid expertise. Lifecore’s business is tied to regulated healthcare markets, so its value proposition depends on quality systems, regulatory compliance, technical reliability, and the ability to scale customer programs from development into commercial supply.

The Bull Case

  • Lifecore’s primary strength is its specialized expertise in regulated pharmaceutical manufacturing and hyaluronic acid-related biomaterials.
  • Sterile injectable production and biomaterial manufacturing require technical precision, regulatory discipline, and quality systems that are not easy for new entrants to replicate.
  • The company also benefits from exposure to markets with long-term growth drivers, including injectables, medical aesthetics, ophthalmology, orthopedics, and drug delivery applications.
  • Its quarterly gross profit and positive operating income suggest that the operating platform can generate value when volumes and mix are favorable.
  • As a smaller specialized CDMO, Lifecore may also be able to offer flexibility and customer attention that larger competitors cannot always provide.

The Bear Case

  • Lifecore’s key weakness is that it remains unprofitable on a net-income basis, with reported net income of negative $6.156 million and diluted EPS of negative $0.19 for the quarter.
  • The company’s valuation metrics are harder to interpret because price-to-earnings, earnings yield, and EV/EBITDA are listed as zero or not meaningful due to negative or unavailable earnings measures.
  • Customer concentration and timing risk also appear important, as the stock reportedly plunged after delayed customer volume growth.
  • The company is much smaller than major CDMO competitors, which may limit its ability to absorb setbacks, fund expansion, or compete for very large global contracts.
  • Its no-dividend profile means shareholders depend on capital appreciation, which can be volatile when earnings visibility is limited.

Key Risks

  • The largest internal risk is execution risk, especially around customer volume ramps, manufacturing schedules, quality performance, and regulatory compliance.
  • A single delayed customer program can have an outsized impact on revenue and sentiment because the company is relatively small.
  • Financial risk is also important because the company reported a net loss, negative EPS, and no dividend, while EV-to-free-cash-flow is shown as elevated at about 44.9.
  • External risks include competition from larger CDMOs, changes in customer outsourcing decisions, regulatory actions, supply chain disruptions, and weaker funding conditions for biotech customers.

What to Watch

UpcomingDuring the most recent reported quarter, Lifecore generated operating revenue of $34.167 million and total revenue of the same amount, showing a focused revenue base for the period.
UpcomingThe company reported total gross profit of $12.075 million and total operating income of $2.567 million, which indicates that core operations were positive at the operating-income level.
UpcomingHowever, net income was negative $6.156 million and both basic and diluted EPS were negative $0.19, so the quarter still reflected bottom-line pressure.
ExpectedFor the next quarter, investor attention will likely focus on whether delayed customer volumes begin to recover or whether the timing issue extends further into the fiscal year.

Price Drivers

  • LFCR’s stock price is likely being driven by revenue growth expectations, customer volume timing, profitability progress, cash flow generation, and confidence in management’s ability to execute.
  • The latest fundamental data shows quarterly operating revenue of about $34.2 million, total gross profit of about $12.1 million, operating income of about $2.6 million, but net income of negative $6.2 million and diluted EPS of negative $0.19.
  • That mix suggests investors may recognize operational improvement at the gross or operating level while still worrying about interest expense, below-the-line costs, leverage, or other factors keeping net income negative.
  • Recent news specifically noted that Lifecore plunged more than 30% after delayed customer volume growth, which indicates the market is highly sensitive to timing of customer ramps and revenue visibility.

Recent News

  • The most directly relevant recent news is that Lifecore’s shares reportedly plunged more than 30% after delayed customer volume growth.
  • That news suggests that the market had expected stronger near-term revenue contribution from customer programs and was disappointed by timing changes.
  • No major acquisition, partnership, or product launch for Lifecore was included in the provided news set.
  • Other news items in the feed referred to the broader hyaluronic acid market and to unrelated companies or macro events, so they should not be treated as direct Lifecore announcements.

Market Trends

  • Broader market trends affecting Lifecore include rising demand for outsourced pharmaceutical manufacturing, increasing use of sterile injectables, and growth in biomaterials such as hyaluronic acid.
  • The hyaluronic acid market is being supported by demand in dermal fillers, orthopedic treatments, eye surgery, skincare, regenerative medicine, and functional health applications.
  • North America remains a leading market because of strong healthcare infrastructure, cosmetic procedure demand, and high awareness of advanced medical and aesthetic products.
  • Asia Pacific is also growing quickly due to rising disposable income, medical tourism, lifestyle changes, and strong beauty markets in countries such as China, Japan, and South Korea.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on LFCR

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show